Philadelphia Pharmaceuticals Company (ASE:PHIL)
Jordan flag Jordan · Delayed Price · Currency is JOD
1.590
0.00 (0.00%)
At close: May 10, 2026

ASE:PHIL Income Statement

Millions JOD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
99.178.768.48.426.6
Revenue Growth (YoY)
1.92%4.64%4.25%-0.12%27.48%-13.77%
Cost of Revenue
4.494.664.644.44.513.47
Gross Profit
4.524.514.1243.913.13
Selling, General & Admin
2.542.522.32.212.592.41
Research & Development
0.440.450.420.440.22-
Operating Expenses
2.992.972.722.652.812.41
Operating Income
1.531.541.41.351.10.72
Interest Expense
-0.29-0.29-0.35-0.34-0.24-0.23
Other Non Operating Income (Expenses)
0.020.03-0000.01
EBT Excluding Unusual Items
1.261.271.041.020.870.49
Pretax Income
1.261.271.041.020.870.49
Income Tax Expense
0.220.270.220.210.160.08
Net Income
1.041.010.820.810.70.41
Net Income to Common
1.041.010.820.810.70.41
Net Income Growth
21.41%22.35%1.77%15.13%70.91%189.48%
Shares Outstanding (Basic)
888888
Shares Outstanding (Diluted)
888888
EPS (Basic)
0.140.130.110.110.090.05
EPS (Diluted)
0.140.130.110.110.090.05
EPS Growth
21.41%22.35%1.77%15.13%70.91%189.49%
Free Cash Flow
0.881.161.531.031.942.94
Free Cash Flow Per Share
0.120.150.200.140.260.39
Dividend Per Share
--0.0700.0700.0600.060
Dividend Growth
---16.67%--
Gross Margin
50.15%49.16%47.03%47.64%46.42%47.47%
Operating Margin
16.99%16.77%15.94%16.12%13.05%10.90%
Profit Margin
11.49%10.96%9.38%9.60%8.33%6.21%
Free Cash Flow Margin
9.73%12.63%17.43%12.30%23.07%44.57%
EBITDA
1.771.781.671.651.220.88
EBITDA Margin
19.67%19.40%19.08%19.62%14.48%13.32%
D&A For EBITDA
0.240.240.280.290.120.16
EBIT
1.531.541.41.351.10.72
EBIT Margin
16.99%16.77%15.94%16.12%13.05%10.90%
Effective Tax Rate
17.75%21.00%21.03%21.02%19.00%16.94%
Advertising Expenses
-0.310.24-0.210.2
Source: S&P Global Market Intelligence. Standard template. Financial Sources.